BCHT: Approval granted for clinical trial application of acellular DTP b-type influenza Haemophilus influenzae combined vaccine
BCHT recently received approval from the National Medical Products Administration to conduct clinical trials for the acellular pertussis-diphtheria-tetanus combined vaccine against Haemophilus influenzae type b. This vaccine can prevent whooping cough, diphtheria, tetanus, and infections caused by Haemophilus influenzae type b, and is suitable for infants aged 2 months and older. If the clinical trials are successful and approved for market launch, it will help the company optimize its product structure, promote the development of its main business, and provide the public with higher quality vaccine options
According to the Zhitong Finance APP, BCHT (688276.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the acellular pertussis-diphtheria-tetanus combined vaccine with Hib.
The acellular pertussis-diphtheria-tetanus combined vaccine with Hib (hereinafter referred to as "DTP-Hib combined vaccine") approved for clinical trials is a vaccine that can simultaneously prevent whooping cough, diphtheria, tetanus, and infections caused by Hib. The target recipients are infants aged 2 months and older, and vaccination can stimulate the immune response to prevent invasive infections caused by whooping cough, diphtheria, tetanus, and Hib.
If the DTP-Hib combined vaccine approved this time successfully completes clinical trials and is approved for market launch, it will further improve the company's combined vaccine research and development pipeline, help optimize the product structure and comprehensive development of the main business, provide the public with higher quality vaccination options, and also assist the company in achieving new breakthroughs in combined vaccines, creating new growth points for the company's performance
